Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trialCarlotta Antoniotti, Chiara Cremolini, Isabelle Boquet et al.|The Lancet Oncology|2022Cited by 268
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trialAndrea Sartore‐Bianchi, Alberto Bardelli, Filippo Pietrantonio et al.|Nature Medicine|2022Cited by 259
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancerMargherita Ambrosini, Filippo Pietrantonio, Benoı̂t Rousseau et al.|Annals of Oncology|2024Cited by 73